AI Article Synopsis
- Neoadjuvant immunotherapy plus chemotherapy shows significant effects on locally advanced esophageal squamous cell carcinoma (LA-ESCC), but the ideal number of treatment cycles remains debated.
- A study involving 100 patients compared the outcomes between those receiving 2 vs. 3 cycles of treatment, focusing on pathologic complete response rates, surgical results, and complications.
- Results showed similar effectiveness and safety between the two cycles, with no notable differences in complications; however, the inflammation marker NLR decreased significantly in some patients after the third cycle, suggesting potential benefits for certain individuals.
Article Abstract
Neoadjuvant immunotherapy combined with chemotherapy has a substantial impact on locally advanced esophageal squamous cell carcinoma (LA-ESCC), but the optimal number of treatment cycles is still controversial. Patients who received 2 or 3 cycles of neoadjuvant immunotherapy combined with chemotherapy followed by esophagectomy to treat LA-ESCC were included. We compared the responses to neoadjuvant therapy, surgical outcomes, perioperative complications, and treatment-related adverse reactions in the two patient groups. A total of 100 patients were included in the study. The pathologic complete response (pCR) rate in patients who received 2 cycles was 18/56 (32.14%), and the pCR rate in patients who received 3 cycles was 14/44 (31.82%) (P=0.97). There was no significant difference in the perioperative parameters, postoperative complications or treatment-related adverse reactions between the two groups (P>0.05). After the third cycle, some patients experienced further relief, with a significant decrease in the NLR (P=0.0.4). In LA-ESCC, the efficacy of both 2 cycles and 3 cycles of neoadjuvant immunotherapy combined with chemotherapy is comparable, with the same tolerance and feasibility. Further evaluation of the inflammation indicator NLR can help identify patients who would benefit from an additional third cycle of neoadjuvant therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660122 | PMC |
| http://dx.doi.org/10.7150/jca.102215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphopenia is an adverse prognostic factor in rectal adenocarcinoma patients receiving long-course chemoradiotherapy.
Radiat Oncol J
December 2024
Radiation Oncology Unit, 1st Department of Radiology, Medical School, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Purpose: Neoadjuvant radiotherapy (RT) or chemoradiotherapy (CRT) is the standard treatment for locally advanced rectal adenocarcinoma. The recent emerging data on preoperative immunotherapy as an effective therapeutic modality for mismatch repair deficient rectal carcinomas suggests that the immune system plays a significant role in tumor eradication. Although RT has been shown to stimulate anti-tumor immunity, it also leads to substantial lymphopenia, hindering the effect of immune response.
View Article and Find Full Text PDFThe spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.
Nat Commun
January 2025
MultiplexDX, s.r.o., Comenius University Science Park, Bratislava, Slovakia.
Current assays fail to address breast cancer's complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome profiling, and explicitly quantifies intratumoral heterogeneity.
View Article and Find Full Text PDFThe characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry.
Oral Oncol
January 2025
Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address:
Objective: Optimizing clinical decision-making in head and neck squamous cell carcinoma (HNSCC) is challenging due to the ambiguous understanding of the immune cell dynamics and immune checkpoints regulation in the disease after the administration of neoadjuvant immunotherapy (NIT).
Methods: HNSCC biopsy samples collected before and after the neoadjuvant treatment are classified into the pathologic response (PR) and the non-pathologic response (NPR) groups according to treatment responses and the expression of immune cells and checkpoints was labeled using multiplex immunohistochemistry (m-IHC).
Results: The populations of CD4 T cells, CD8 T cells, regulatory T cells (Treg), PD-1, and PD-L1 were particularly higher in the PR group than the NPR group in pre-treatment tissues, with the p-values of log-transformed positive cell density <0.
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
Clin Cancer Res
January 2025
University Hospital Essen, Essen, Germany.
Antibodies targeting immune checkpoints, such as PD-1, PD-L1, or CTLA-4, have transformed the treatment of patients with lung cancers. Unprecedented rates of durable responses are achieved in an imperfectly characterized population of patients with metastatic disease. More recently, immune checkpoint inhibitors have been explored in patients with resectable non-small-cell lung cancers.
View Article and Find Full Text PDFAnalysis of the short-term efficacy of 2 versus 3 cycles of neoadjuvant immunotherapy combined with chemotherapy in patients with esophageal squamous cell carcinoma.
J Cancer
January 2025
Department of Thoracic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Article Synopsis
- Neoadjuvant immunotherapy plus chemotherapy shows significant effects on locally advanced esophageal squamous cell carcinoma (LA-ESCC), but the ideal number of treatment cycles remains debated.
- A study involving 100 patients compared the outcomes between those receiving 2 vs. 3 cycles of treatment, focusing on pathologic complete response rates, surgical results, and complications.
- Results showed similar effectiveness and safety between the two cycles, with no notable differences in complications; however, the inflammation marker NLR decreased significantly in some patients after the third cycle, suggesting potential benefits for certain individuals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!